UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
December 16, 2019
Commission File Number: 001 - 38178
Zealand Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Sydmarken 11
2860 Søborg (Copenhagen)
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release (“company announcement”) of Zealand Pharma A/S or the Company, dated December 13, 2019, that discloses information on transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons. Exhibit 99.2 provides further detail of the transaction.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Zealand Pharma A/S |
| | |
| By: | /s/ Matthew Dallas |
| | |
| | Name: | Matthew Dallas |
| | Title: | Chief Financial Officer |
Date: December 16, 2019
2
EXHIBIT INDEX
Exhibit
No. | | Description |
| | |
99.1 | | Press release dated December 13, 2019 disclosing information about manager transactions |
| | |
99.2 | | AST — shares |
3
